Atopix Recruits First Patient In Phase 2 Trial Of OC459 For Atopic Dermatitis
11/19/2013 8:03:46 AM
ABINGDON, England--(BUSINESS WIRE)--Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, today announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).
Help employers find you! Check out all the jobs and post your resume.
comments powered by